VOYA Investment Management
KALV

VOYA Investment Management’s KalVista Pharmaceuticals KALV Stock Holding History

VOYA Investment Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,714
Closed -$121K – 2549
2025
Q2 		$121K Buy
10,714
+475
+5% +$5.81K ﹤0.01% 2449
2025
Q1 		$118K Sell
10,239
-2,151
-17% -$22K ﹤0.01% 2396
2024
Q4 		$105K Sell
12,390
-931
-7% -$9.64K ﹤0.01% 2566
2024
Q3 		$154K Sell
13,321
-94
-0.7% -$1.18K ﹤0.01% 2556
2024
Q2 		$158K Buy
13,415
+3,125
+30% +$36.5K ﹤0.01% 2547
2024
Q1 		$122K Sell
10,290
-2,249
-18% -$30K ﹤0.01% 2587
2023
Q4 		$154K Buy
12,539
+2,170
+21% +$19.7K ﹤0.01% 2652
2023
Q3 		$99.9K Hold
10,369
– – ﹤0.01% 2734
2023
Q2 		$93.3K Buy
+10,369
New +$95.6K ﹤0.01% 2808
2021
Q2 		– Sell
-8,195
Closed -$211K – 2855
2021
Q1 		$211K Buy
+8,195
New +$215K ﹤0.01% 2511

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VOYA Investment Management's KALV Position: Q3 2025 in Review

VOYA Investment Management sold out of KalVista Pharmaceuticals (KALV) in Q3 2025, closing a stake of 10,714 shares — an estimated $121K sold.

VOYA Investment Management first reported a position in KALV in Q1 2021 and held it in 10 quarters. The position peaked at $211K in Q1 2021. 145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.

  • VOYA Investment Management reported no remaining KalVista Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • VOYA Investment Management sold 10,714 KalVista Pharmaceuticals shares in Q3 2025, an estimated $121K.
  • VOYA Investment Management first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 10 quarters.
  • VOYA Investment Management's KalVista Pharmaceuticals position peaked at $211K in Q1 2021.
  • 145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.

Based on VOYA Investment Management's 13F filing for Q3 2025, filed 9 Oct 2025.